Optimal Length of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Role of P2Y12 Inhibitor Monotherapy

Authors

Elizabeth A. Schacht, University of LynchburgFollow

Specialty

Cardiology

Advisor

Professor Elyse Watkins, DHSc, PA-C, DFAAPA

Abstract

ABSTRACT

Purpose: The purpose of this article is to provide a review of the most recent literature regarding the optimal treatment interval for dual antiplatelet therapy (DAPT) and the role of P2Y12 inhibitor monotherapy in patients with coronary artery disease (CAD) who have undergone percutaneous coronary intervention (PCI).

Method: A PubMed advanced literature search was completed implementing the search terms “dual antiplatelet therapy,” “PCI,” and “monotherapy.” Appropriate articles were identified and serve as the basis for this topic review.

Results: Search parameter filters applied include “best match” and “5 years or younger.” The preliminary search results numbered 56, but after applying various filters and excluding some articles for irrelevant content, 3 articles were selected. These articles include findings from the following randomized clinical trials: STOPDAPT-2 and SMART-CHOICE.

Conclusion: A reduction in bleeding events without an associated increase in death or major ischemic events was observed in patients who underwent PCI with drug-eluting stent placement and completed a shorter duration of DAPT followed by P2Y12 inhibitor monotherapy compared to patients completed a longer course of DAPT. Further research is required in other patient populations to account for the study’s limitations.

Keywords: dual antiplatelet therapy, PCI, monotherapy

Recommended Citation

Schacht EA. Optimal Length of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Role of P2Y12 Inhibitor Monotherapy. University of Lynchburg DMSc Doctoral Project Assignment Repository. 2020; 2(4).